News | March 18, 2026
Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
